Login to Your Account


Jazz paying $1B for Gentium; gains rights to defibrotide

By Cormac Sheridan
Staff Writer

Friday, December 20, 2013
DUBLIN – Cashing in on the steep climb in its valuation over the last six months, Gentium SpA agreed to a $57-per-share acquisition deal with Jazz Pharmaceuticals plc, which values the company at about $1 billion.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription